



Correction to: Behavior of metastatic breast cancer according to subtype

Margot Van Mechelen¹ · Anke Van Herck¹ · Kevin Punie^{2,4,6} · Ines Nevelsteen² · Ann Smeets² · Patrick Neven² · Caroline Weltens² · Sileny Han² · Adriaan Vanderstichele² · Giuseppe Floris^{2,5,7} · Jean-Pierre Lobelle³ · Hans Wildiers^{2,4,6}

Published online: 7 January 2021

© Springer Science+Business Media, LLC, part of Springer Nature 2021

Correction to:

Breast Cancer Research and Treatment (2020) 181:115–125

<https://doi.org/10.1007/s10549-020-05597-3>

In the original publication of the article, Table 1 was published incorrectly. The corrected Table 1 is given below.

The original article can be found online at <https://doi.org/10.1007/s10549-020-05597-3>.

✉ Hans Wildiers
hans.wildiers@uzleuven.be

¹ Department of Internal Medicine, University Hospitals Leuven, Leuven, Belgium

² Multidisciplinary Breast Centre, University Hospitals Leuven, Leuven, Belgium

³ Consultant in Statistics, Beernem, Belgium

⁴ Department of General Medical Oncology, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium

⁵ Department of Imaging and Pathology, Laboratory of Translational Cell & Tissue Research, University Hospitals Leuven, Leuven, Belgium

⁶ Department of Oncology, KU Leuven, Leuven, Belgium

⁷ Department of Pathology, KU Leuven, Leuven, Belgium

Table 1 Breast cancer patients characteristics according to subtype

	Lum A		Lum B1		Lum B2		Her2pos		TN		All patients	
	n	%	n	%	n	%	n	%	n	%	n	%
Median age at diagnosis in years (range)	57 (25-96)		58 (22-95)		55 (27-94)		57 (30-90)		53 (23-96)		57 (22-96)	
Total number of patients	3101	51.9	1256	21.0	289	4.8	224	3.8	188	3.2	177	3
Tumor setting at diagnosis												
Primary metastatic	125	4.0	71	5.7	45	15.6	0	0	28	14.9	1*	0.6
Early breast cancer	2976	96.0	1185	94.3	244	84.4	224	100.0	160	85.1	176	99.4
Later development of metastases												
No	2734	91.9	943	79.6	191	78.3	203	90.6	112	70.0	142	80.1
Yes (= Secondary metastases)	242	8.1	242	20.4	53	21.7	21	9.4	48	30.0	34	19.9
Neoadjuvant EBC												
Later development of metastases	212	6.8	104	8.3	30	10.3	43	19.2	22	11.7	59	33.3
No	150	70.8	69	66.4	19	63.3	34	79.1	12	54.6	44	74.58
Yes (= Secondary metastases)	62	29.3	35	33.7	11	36.7	9	20.9	10	45.5	15	25.42
Upfront surgery EBC												
Later development of metastases	2764	89.1	1081	86.1	214	74.0	181	80.8	138	73.4	117	66.1
No	2584	93.5	874	80.9	172	80.4	169	93.4	100	72.5	98	83.8
Yes (= Secondary metastases)	180	5.5	207	19.2	42	19.6	12	5.6	38	27.5	19	16.2
Pathological stage												
I A	1212	44.5	259	24.4	80	38.8	50	27.8	47	35.3	26	22.8
I B	79	2.9	16	1.5	2	1.0	6	3.3	1	0.8	2	1.8
II A	753	27.7	364	34.3	55	26.7	43	23.9	32	24.1	33	29.0
II B	372	13.7	220	20.7	30	14.6	43	23.9	24	18.1	23	20.2
III A	224	8.2	137	12.9	27	13.1	29	16.1	22	16.5	18	15.8
III B	15	0.6	12	1.1	2	1.0	1	0.6	0	0.0	1	0.9
III C	68	2.5	53	5.0	10	4.9	8	4.4	7	5.3	11	9.7
Total	2723		1061		206		180		133		114	
Missing data	41		20		8		1		5		3	

EBC = early breast cancer.
 LumA = Luminal A = ER and/or PR positive, HER2 negative and grade 1 or 2
 LumB1 = Luminal B1 = ER and/or PR positive, HER2 negative and grade 3
 LumB2 = Luminal B2 = ER and/or PR positive, HER2 positive
 Her2pos = HER2 positive (non-luminal) = ER and PR negative, HER2 positive
italic indicates % compared to total number of pts for that row
bold indicates % compared to all pts of that group (column)
underlined indicates % of no versus yes
italic and underlined indicates % of known tumor stage per subtype
 *Patient with local breast cancer scheduled for neoadjuvant systemic therapy within a clinical trial. On the trial PET scan at the starting day, liver metastases were detected. She continued the study, had a very good response on the 'neoadjuvant' treatment, and went on to maximal local therapy (with complete pathological response in the breast).

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.